HUMAN ISLET CELL TRANSPLANTATION FOR REVERSAL OF TYPE I DIABETES MELLITUS

人类胰岛细胞移植逆转 I 型糖尿病

• 批准号: 7378375
• 负责人: DOLCA A THOMAS
• 金额: $ 6.4万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378375
• 关键词: HUMAN; ISLET; CELL; TRANSPLANTATION; REVERSAL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Type I insulin-dependent diabetes mellitus affects approximately 800,000 people in the U.S. alone. Despite the development of exogenous insulin and multiple portocols evaluating its mode of delivery, type I diabetics suffer multiple complications due to the lack of consistent glucose homeostasis. Type I diabetics usually only have deficiency in the endocrine function of the pancreas, and therefore only require replacement of the Islets of Langerhans. Pancreatic islet transplantation is a biologic replacement strategy that attempts to replace the insulin producing Islets of Langerhans and represents a potential cure for the disease process. The goal of this study is to determine if pancreatic islet transplantation, via the normal endocrine axis of the pancreas, can achieve either insulin independence or a significant decrease in insulin requirements in 10 consecutive type I diabetic patients.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。I型胰岛素依赖型糖尿病仅在美国就影响约80万人。尽管外源性胰岛素和多门静脉输注的发展评估其交付模式，I型糖尿病患者遭受多种并发症，由于缺乏一致的葡萄糖稳态。I型糖尿病患者通常只有胰腺内分泌功能不足，因此只需要更换胰岛。胰岛移植是一种生物替代策略，试图替代产生胰岛素的胰岛，并代表了治疗疾病过程的潜在方法。本研究的目的是确定胰岛移植，通过正常的胰腺内分泌轴，可以实现胰岛素的独立性或显着减少胰岛素的需求，在10个连续的I型糖尿病患者。